Alcon Overview

  • Year Founded
  • 1945

Year Founded

  • Status
  • Public

  • Employees
  • 25,942

Employees

  • Stock Symbol
  • ALC

Stock Symbol

  • Investments
  • 32

  • Share Price
  • $75.06
  • (As of Thursday Closing)

Alcon General Information

Description

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Contact Information

Website
www.alcon.com
Formerly Known As
Alcon Universal, Socit Fromagre Nestl
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Chemin de Blandonnet 8
  • Vernier
  • 1214 Geneva
  • Switzerland
+41 062
Primary Industry
Surgical Devices
Other Industries
Other Devices and Supplies
Stock Exchange
SWX
Corporate Office
  • Chemin de Blandonnet 8
  • Vernier
  • 1214 Geneva
  • Switzerland
+41 062

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alcon Stock Performance

As of 19-Nov-2026, Alcon’s stock price is $75.06. Its current market cap is $36.1B with 480M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$75.06 $74.06 $61.45 - $88.50 $36.1B 480M 1.07M $1.37

Alcon Financials Summary

As of 30-Sep-2026, Alcon has a trailing 12-month revenue of $11B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 34,994,919 43,173,308 42,168,520 42,667,754
Revenue 10,984,000 10,401,000 9,911,000 9,455,000
EBITDA 2,665,000 2,625,000 2,592,000 2,197,000
Net Income 666,000 980,000 1,018,000 974,000
Total Assets 31,368,000 31,555,000 30,347,000 29,614,000
Total Debt 5,331,000 5,240,000 5,136,000 5,135,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alcon Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alcon‘s full profile, request access.

Request a free trial

Alcon Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spu
Surgical Devices
Geneva, Switzerland
25,942 As of 2025

San Ramon, CA
 

Aliso Viejo, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alcon Competitors (17)

One of Alcon’s 17 competitors is The Cooper Companies, a Corporation company based in San Ramon, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
The Cooper Companies Corporation San Ramon, CA
Glaukos Formerly VC-backed Aliso Viejo, CA
biolitec Corporation Vienna, Austria
Stryker Formerly VC-backed Portage, MI
Bausch + Lomb Formerly PE-Backed Bridgewater, NJ
You’re viewing 5 of 17 competitors. Get the full list »

Alcon Patents

Alcon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260345390-A1 Automated docking of an ophthalmic system to an eye Pending 05-May-2025
WO-2026234495-A1 Automated docking of an ophthalmic system to an eye Pending 05-May-2025
US-20260349277-A1 Generative artificial intelligence for manufacturing intraocular lenses Pending 05-May-2025
WO-2026234490-A1 Generative artificial intelligence for manufacturing intraocular lenses Pending 05-May-2025
US-20260345228-A1 Aspirating diathermy probe Pending 01-May-2025 A61B18/1477
To view Alcon’s complete patent history, request access »

Alcon Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alcon Investments & Acquisitions (32)

Alcon’s most recent deal was a Merger/Acquisition with Neurotech for . The deal was made on 20-Oct-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Neurotech 20-Oct-2026 Merger/Acquisition Drug Discovery
Lensar 16-Mar-2026 Merger/Acquisition Other Devices and Supplies
LumiThera 02-Sep-2025 Merger/Acquisition Other Devices and Supplies
Aurion Biotech 24-Mar-2025 Merger/Acquisition Biotechnology
ViaLase 03-Sep-2024 Later Stage VC Surgical Devices
You’re viewing 5 of 32 investments and acquisitions. Get the full list »

Alcon ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

16.23 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Medical Devices

Subindustry

of 209

Rank

Percentile

To view Alcon’s complete esg history, request access »

Alcon Exits (3)

Alcon’s most recent exit was on 22-Oct-2009 from Potentia Pharmaceuticals. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Potentia Pharmaceuticals 22-Oct-2009 Completed
Optobionics 01-Jun-2000 Completed
  • 4 buyers
MID Labs 01-Jan-1985 Merger/Acquisition Completed
To view Alcon’s complete exits history, request access »

Alcon Affiliates

Subsidiaries (5)

Name Industry Location Year Founded
Aurion Biotech Seattle, WA 2021
LumiThera Poulsbo, WA 2013
BELKIN Vision Yavne, Israel 2013
Neurotech Cumberland, RI 2002
Kala Pharmaceuticals (EYSUVIS and INVELTYS) Arlington, MA

Alcon FAQs

  • When was Alcon founded?

    Alcon was founded in 1945.

  • Where is Alcon headquartered?

    Alcon is headquartered in Geneva, Switzerland.

  • What is the size of Alcon?

    Alcon has 25,942 total employees.

  • What industry is Alcon in?

    Alcon’s primary industry is Surgical Devices.

  • Is Alcon a private or public company?

    Alcon is a Public company.

  • What is Alcon’s stock symbol?

    The ticker symbol for Alcon is ALC.

  • What is the current stock price of Alcon?

    As of 19-Nov-2026 the stock price of Alcon is $75.06.

  • What is the current market cap of Alcon?

    The current market capitalization of Alcon is $36.1B.

  • What is Alcon’s current revenue?

    The trailing twelve month revenue for Alcon is $11B.

  • Who are Alcon’s competitors?

    The Cooper Companies, Glaukos, biolitec, Stryker, and Bausch + Lomb are some of the 17 competitors of Alcon.

  • What is Alcon’s annual earnings per share (EPS)?

    Alcon’s EPS for 12 months was $1.37.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process